A similar relationship between baseline BCVA and functional outcome has been observed in patients with macular edema who received antivascular endothelial growth factor (VEGF) therapy or CS injections for retinal diseases such as age-related macular degeneration or diabetic macular edema.27,28 These results emphasize baseline BCVA as a major prognostic factor for the overall outcome and importance of a timely start of treatment. The gene discussed is VEGFA; the disease is diabetic macular edema.